share_log

藥明合聯：截至2024年2月29日止股份發行人的證券變動月報表

WUXI XDC: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 29 February 2024

Hong Kong Stock Exchange ·  Mar 5 17:00
Summary by Futu AI
藥明合聯生物技術有限公司（WuXi XDC Cayman Inc.），股份代號02268，於2024年3月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年2月29日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在報告期內維持不變，法定/註冊股本總額為500,000美元，共10,000,000,000股普通股，每股面值0.00005美元。此外，公司根據2021年及2023年的股份期權計劃，詳列了各期權計劃的授出日期、行使價及股份期權數目，但在報告期內並無新股份因行使股份期權而發行。藥明合聯確認，所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
藥明合聯生物技術有限公司（WuXi XDC Cayman Inc.），股份代號02268，於2024年3月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年2月29日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在報告期內維持不變，法定/註冊股本總額為500,000美元，共10,000,000,000股普通股，每股面值0.00005美元。此外，公司根據2021年及2023年的股份期權計劃，詳列了各期權計劃的授出日期、行使價及股份期權數目，但在報告期內並無新股份因行使股份期權而發行。藥明合聯確認，所有證券發行均已獲得董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
Pharmaceutical United Biotechnology Co., Ltd. (WuXi XDC Cayman Inc.) , share code 02268, filed with Hong Kong Trading and Settlement Limited on 5 March 2024 an updated Monthly Statement of Changes in Securities, reporting the changes in the Company's share capital as of 29 February 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED DURING THE REPORTING PERIOD WITH A TOTAL STATUTORY/REGISTERED SHARE CAPITAL OF $500,000, TOTALING 10,000,000,000 SHARES OF ORDINARY SHARES WITH A FACE VALUE OF $0.00005 PER SHARE. In addition, under the 2021 and 2023 share option plans, the Company details the grant dates, exercise prices and number of share options for each option plan, but no new shares were issued during the reporting period as a result of the exercise of the share options. Pharmaceutical Union confirms that all securities issuance has been authorised by the Board of Directors and complies with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited.
Pharmaceutical United Biotechnology Co., Ltd. (WuXi XDC Cayman Inc.) , share code 02268, filed with Hong Kong Trading and Settlement Limited on 5 March 2024 an updated Monthly Statement of Changes in Securities, reporting the changes in the Company's share capital as of 29 February 2024. THE REPORT SHOWS THAT THE COMPANY'S STATUTORY/REGISTERED SHARE CAPITAL AND ISSUED SHARES REMAINED UNCHANGED DURING THE REPORTING PERIOD WITH A TOTAL STATUTORY/REGISTERED SHARE CAPITAL OF $500,000, TOTALING 10,000,000,000 SHARES OF ORDINARY SHARES WITH A FACE VALUE OF $0.00005 PER SHARE. In addition, under the 2021 and 2023 share option plans, the Company details the grant dates, exercise prices and number of share options for each option plan, but no new shares were issued during the reporting period as a result of the exercise of the share options. Pharmaceutical Union confirms that all securities issuance has been authorised by the Board of Directors and complies with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.